A Vancouver-based biotechnology company is moving closer to turning science fiction into clinical reality, backed by tens of millions in federal dollars and a partnership with one of the world's largest pharmaceutical firms.
Aspect Biosystems announced Thursday that it has received $79 million from the federal Strategic Response Fund (SRF) as part of a $280-million project aimed at significantly expanding its clinical development capabilities and strengthening its biomanufacturing platform for advanced cellular medicines. The company will contribute the remaining $201 million to the initiative.
Founded in 2013 as a spinout from the University of British Columbia, Aspect specialises in 3D bioprinting — a process that combines living cells derived from stem cells with biomaterials such as hydrogel polymers to create functional human tissue. Those polymers absorb water, giving the resulting structures a soft, pliable texture remarkably similar to natural human tissue.
A Potential Game-Changer for Organ Disease
The implications of this technology are significant. Bioprinted tissues could theoretically be used to repair or replace damaged organs — including the pancreas in patients living with Type 1 diabetes — potentially eliminating the need for traditional organ transplants and their associated risks, rejection complications, and painful recovery processes.
Aspect CEO Tamer Mohamed described the federal investment as a defining moment for the company.
"We are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world," Mohamed said.
Mohamed called the funding "a powerful vote of confidence" in Aspect's trajectory as it works toward meaningful patient impact.
Growing Stack of Government and Private Backing
This latest federal commitment builds on a growing foundation of public and private investment in Aspect's work. In July 2024, the company secured $49 million through the federal Strategic Innovation Fund alongside nearly $24 million from the Province of British Columbia to establish its biomanufacturing facility. Then, in January 2025, Aspect raised $115 million USD — approximately $165 million CAD — in a Series B funding round led by American biotech investor Dimension.
Aspect has also been working alongside Novo Nordisk, the Danish pharmaceutical giant behind blockbuster diabetes and obesity drugs Ozempic and Wegovy, since April 2023. That partnership expanded in January 2025, with Aspect integrating select manufacturing, research, and development expertise from Novo Nordisk's operations in the United States and Denmark into its Canadian facilities. In return, Novo Nordisk received defined rights to expand its role in the venture at a later stage.
From Pre-Clinical to Clinical: The Road Ahead
As recently as last year, Mohamed acknowledged that Aspect remained a pre-clinical stage company, with the goal of advancing to clinical-stage operations over the coming years. The new federal investment is expected to accelerate that timeline, enhancing the company's ability to move its bioprinted tissue therapies through the development pipeline and, eventually, into patients.
Canada's biotech sector has been increasingly drawing attention as a hub for life sciences innovation, and Aspect's trajectory — from a university lab in British Columbia to a company with hundreds of millions in backing and a partnership with a global pharmaceutical leader — reflects growing confidence in Canadian-made medical breakthroughs.
Source: BetaKit. Original reporting by Michael Torres.